Nevus of Ota: The Q-Switched Battle Against Dermal Pigment
What Is Nevus of Ota?
Nevus of Ota is dermal melanocytosis along the ophthalmic and maxillary divisions of the trigeminal nerve — slate-blue or blue-brown patches typically unilateral across forehead, temple and periorbital area. About half appear at birth or in early childhood; slightly more common in women and in East Asian populations, sometimes with scleral involvement.
Why It Is a Long Campaign
Pigment sits deep in the dermis; each Q-switched pass clears only part of it, and melanocytes can repopulate. Clinical experience: 8-15+ sessions at 2-3 month intervals; slate-gray shades often clear more slowly than deep blue.
Treatment Options
- Mainstay: Q-switched 1064 nm at fluence producing mild graying without bleeding.
- Adjunct: picosecond 1064 nm reduces thermal injury and PIH, valuable in darker skin; coexisting epidermal components are staged.
- Periorbital safety: corneal shields mandatory near the eyelids, treated by experienced physicians.
Configuration Notes
Dermal pigment work demands output stability and beam uniformity — free-running fluence drift causes hypopigmentation and scarring. A dual-wavelength Q-switched platform is the baseline; adding a picosecond platform improves darker-skin tolerance.
FAQ
Can nevus of Ota turn malignant?
The vast majority remain stable for life; rare uveal melanoma association (with scleral involvement) justifies ophthalmic follow-up — cosmetic treatment does not change this.
What age can treatment start?
School age is common; earlier treatment often needs fewer sessions and benefits psychosocial development — assessed by pediatric dermatology.